DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes

Summary

SGLT2 inhibitors have demonstrated to mitigate cardiorenal risk in people with type 2 diabetes and are likely to play an increasingly large role in the treatment of patients with diabetes, chronic kidney disease and hypertension. Yet the underlying mechanisms of its protective effects are incompletely understood and the salutary effect may be altered by dietary factors such as sodium intake. Therefore, carefully designed mechanistic trials are needed to better understand the interplay between ertugliflozin and salt intake and to potentially modify salt intake to maximize treatment response.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Type 2 Diabetes

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

18 to 85 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Amsterdam UMC, location VUmc

Last updated on ClinicalTrials.gov

May 21, 2025

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites